Insulet (PODD) | Financial Analysis & Statements

Insulet Corporation | Large-cap | Healthcare

$296.51

-1.39%

Insulet vs Abbott Laboratories Insulet vs Boston Scientific Insulet vs Stryker Insulet vs Medtronic plc Insulet vs Edwards Lifesciences Insulet vs S&P 500 | Market

Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2.1B

Gross Profit 1.4B 69.79%

Operating Income 308.9M 14.91%

Net Income 418.3M 20.19%

EPS (Diluted) $5.78

Balance Sheet Metrics

Total Assets 3.1B

Total Liabilities 1.9B

Shareholders Equity 1.2B

Debt to Equity 1.55

Cash Flow Metrics

Operating Cash Flow 403.1M

Free Cash Flow 296.3M

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Insulet Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue	2.1B	1.7B	1.3B	1.1B	904.4M
Cost of Goods Sold	625.9M	537.2M	499.7M	346.7M	322.1M
Gross Profit	1.4B	1.2B	805.6M	752.1M	582.3M
Operating Expenses	1.1B	939.9M	768.0M	626.1M	530.8M
Operating Income	308.9M	220.0M	37.6M	126.0M	51.5M
Pre-tax Income	300.2M	214.6M	9.8M	20.5M	9.7M
Income Tax	-118.1M	8.3M	5.2M	3.7M	2.9M
Net Income	418.3M	206.3M	4.6M	16.8M	6.8M
EPS (Diluted)	$5.78	$2.94	$0.07	$0.24	$0.10

Income Statement Trend

Insulet Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets	1.9B	1.6B	1.3B	1.3B	1.2B
Non-Current Assets	1.2B	1.0B	937.1M	719.0M	624.2M
Total Assets	3.1B	2.6B	2.3B	2.0B	1.9B
Liabilities
Current Liabilities	528.4M	451.2M	364.7M	228.8M	207.8M
Non-Current Liabilities	1.3B	1.4B	1.4B	1.3B	1.1B
Total Liabilities	1.9B	1.9B	1.8B	1.5B	1.3B
Equity
Total Shareholders Equity	1.2B	732.7M	476.4M	556.3M	603.6M

Balance Sheet Composition

Insulet Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income	418.3M	206.3M	4.6M	16.8M	6.8M
Operating Cash Flow	403.1M	115.2M	14.0M	-91.3M	87.0M
Investing Activities
Capital Expenditures	-	-	-	-	-
Investing Cash Flow	-12.2M	-10.2M	-33.8M	40.0M	180.5M
Financing Activities
Dividends Paid	-	-	-	-	-
Financing Cash Flow	-48.2M	-40.5M	-56.6M	17.2M	573.8M
Free Cash Flow	296.3M	36.5M	-38.3M	-190.8M	-82.5M

Cash Flow Trend

Insulet Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 55.44

Forward P/E 79.50

Price to Book 16.27

Price to Sales 9.85

PEG Ratio 79.50

Profitability Ratios

Profit Margin 18.29%

Operating Margin 15.61%

Return on Equity 37.92%

Return on Assets 6.94%

Financial Health

Current Ratio 4.47

Debt to Equity 131.41

Beta 1.38

Per Share Data

EPS (TTM) $5.55

Book Value per Share $18.91

Revenue per Share $31.34

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
podd	21.7B	55.44	16.27	37.92%	18.29%	131.41
Abbott Laboratories	231.9B	17.31	4.75	30.65%	31.89%	27.09
Boston Scientific	149.9B	73.94	6.75	9.50%	11.58%	52.16
Stryker	148.0B	52.39	7.07	14.26%	12.31%	82.92
Medtronic plc	110.3B	23.84	2.30	9.51%	13.90%	61.39
Edwards Lifesciences	43.3B	30.51	4.27	16.51%	75.71%	6.86

Financial data is updated regularly. All figures are in the company's reporting currency.